Expression of E-cadherin, Snail and Hakai in epithelial cells isolated from the primary tumor and from peritumoral tissue of invasive ductal breast carcinomas by MAKDISSI, F.B.A. et al.
Faculdade de Medicina 
de Ribeirão Preto
Campus
Ribeirão Preto
Institutional Sponsors
The Brazilian Journal of Medical and Biological Research is partially financed by 
Braz J Med Biol Res, December 2009, Volume 42(12) 1128-1137
Expression of E-cadherin, Snail and Hakai in epithelial cells 
isolated from the primary tumor and from peritumoral tissue of 
invasive ductal breast carcinomas
F.B.A. Makdissi, L.V.S.T. Machado, A.G.C. Oliveira, T.T. Benvenuti, M.L.H. Katayama, M.M. 
Brentani, C.A.B.T. Osório, M. Mourão Netto, E.C. Lyra, F. Carvalho, J.C.S. Góes and M.A.A.K. 
Folgueira
ISSN 0100-879X
BIOMEDICAL SCIENCES
AND
CLINICAL INVESTIGATIONwww.bjournal.com.br
  Volume 42 (12) 1119-1247 December 2009
Expression of E-cadherin, Snail and Hakai in 
epithelial cells isolated from the primary tumor 
and from peritumoral tissue of invasive 
ductal breast carcinomas
F.B.A. Makdissi1,2*, L.V.S.T. Machado1,3*, A.G.C. Oliveira1,2*, T.T. Benvenuti1, 
M.L.H. Katayama1, M.M. Brentani1, C.A.B.T. Osório2, M. Mourão Netto2, 
E.C. Lyra1,4, F. Carvalho2, J.C.S. Góes4 and M.A.A.K. Folgueira1
1Disciplina de Oncologia, Departamento de Radiologia, Faculdade de Medicina, 
Universidade de São Paulo, São Paulo, SP, Brasil
2Hospital do Câncer A.C. Camargo, São Paulo, SP, Brasil
3Programa de Pós-Graduação Interunidades em Biotecnologia, 
Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brasil 
4Instituto Brasileiro de Controle do Câncer, São Paulo, SP, Brasil
Abstract
Epithelial intercellular cohesion, mainly mediated by E-cadherin (CDH1) expression and function, may be deregulated during 
cancer cell invasion of adjacent tissues and lymphatic and vascular channels. CDH1 expression is down-modulated in invasive 
lobular breast carcinomas but its regulation in invasive ductal carcinomas (IDC) is less clear. CDH1 expression is repressed by 
transcription factors such as Snail (SNAI1) and its product is degraded after Hakai ubiquitination. We compared CDH1, SNAI1 
and HAKAI mRNA expression in IDC and paired adjacent normal breast tissue and evaluated its relation with node metastasis 
and circulating tumor cells. Matched tumor/peritumoral and blood samples were collected from 30 patients with early IDC. Epi-
thelial cells from each compartment (tumor/peritumoral) were recovered by an immunomagnetic method and gene expression 
was determined by real-time RT-PCR. There were no differences in CDH1, SNAI1 and HAKAI mRNA expression between tumor 
and corresponding peritumoral samples and no differential tumoral gene expression according to nodal involvement. Another 
30 patients with a long-term follow-up (at least 5 years) and a differential prognosis (good or poor, as defined by breast cancer 
death) had E-cadherin and Snail protein detected by immunohistochemistry in tumor samples. In this group, E-cadherin-positive 
expression, but not Snail, may be associated with a better prognosis. This is the first report simultaneously analyzing CDH1, 
SNAI1 and HAKAI mRNA expression in matched tumor and peritumoral samples from patients with IDC. However, no clear 
pattern of their expression could distinguish the invasive tumor compartment from its adjacent normal tissue.
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To invade, breast cancer cells reduce their intercellular 
cohesion, lose polarity, enhance their motility and proteolytic 
activity, and acquire mesenchymal cell characteristics, 
undergoing a dramatic remodeling of the cytoskeleton in 
a process similar to the epithelial-mesenchymal transi-
tion (EMT) that takes place during embryogenesis (1,2). 
Invasive carcinomas may then spread through lymphatic 
or vascular channels and metastasize to regional lymph 
nodes and distant sites.
Functional loss of E-cadherin (CDH1) in an epithelial cell 
has been considered a hallmark of EMT. CDH1 expression 
may be repressed by transcription factors such as Snail 
(SNAI1), ZEB1 and Slug (2-4). Snail belongs to a family of 
zinc-finger-containing transcriptional repressors implicated 
in the regulation of the EMT phenomenon (5) and, accord-
ingly, Snail transfection into epithelial cells leads to a more 
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fibroblastic phenotype (3).
E-cadherin expression may also be controlled by its 
internalization and subsequent degradation by the prote-
osome system, mainly mediated by Hakai, an E3 ubiquitin-
ligase that interacts with E-cadherin, inducing ubiquitination 
of the complex. Expression of Hakai in epithelial cells 
disrupts cell-cell contacts and enhances endocytosis of 
E-cadherin and cell motility (6).
Although in invasive lobular carcinoma of the breast 
there is almost a universal loss of E-cadherin expression, 
in non-lobular invasive carcinomas, its absence is not so 
common, but may play a role in progression, development 
of distant metastases and recurrence (7-9).
Our aim was to determine whether there are differ-
ences in E-cadherin, Snail and Hakai transcript expression 
(related to the EMT) between paired tumor and adjacent 
normal tissue from patients with invasive ductal breast 
carcinoma. Additionally, we also determined whether the 
tumoral expression of these genes could be associated 
with cell shedding and consequent regional and distant 
metastases.
Patients and Methods
Thirty patients were prospectively recruited at two 
reference cancer centers in São Paulo, Brazil: Hospital do 
Câncer A.C. Camargo and Instituto Brasileiro de Controle 
do Câncer, from December 2003 to November 2005. The 
study was approved by the Institutional Ethics Committee 
and written informed consent was signed by all participants. 
Fresh tumor and adjacent normal tissue samples were 
collected from these patients during tumor resection for 
epithelial cell recovery and gene expression analysis.
The median age of the patients was 53 years (Table 
1), 76.7% of the women were postmenopausal, 53.3% 
presented T1 lesions, and 50.0% presented lymph node 
involvement. Thirty-five percent of the patients presented 
pathological stage III disease and none of them had distant 
metastases, as evaluated by abdominal ultrasound, chest 
radiographs (posteroanterior and lateral) and a bone scan. 
Invasive ductal carcinoma was diagnosed in all patients, 
being histologic grade 3 in 27.6% of cases. Immunohis-
tochemical expression of estrogen receptor, progesterone 
receptor and ERBB2 was detected in 86.7, 76.7 and 24.1% 
of the tumors, respectively. None of the patients had been 
previously treated for a breast carcinoma.
Another group of 30 patients with invasive ductal car-
cinoma diagnosed between 1994 and 1995 at Hospital do 
Câncer A.C. Camargo with a long-term follow-up (at least 
5 years, median 93.3 months) had paraffin-embedded 
tumor samples available for immunohistochemistry reac-
tions. Median age was 48.5 years (Table 2) and patients 
had at least 13 lymph nodes dissected during the surgical 
procedure. Twenty-one of these patients were assigned to a 
good prognosis group since they did not present lymph node 
involvement at diagnosis and had not developed regional 
or distant metastases during the follow-up period. Nine pa-
tients were assigned to a poor prognosis group since they 
presented histopathological involvement of axillary nodes 
upon diagnosis. In addition, 1 of them presented a distant 
metastasis at diagnosis (clinical stage IV disease) and the 
other 8 developed distant metastases. Breast cancer death 
followed after 18.1-80 months. Seventy-one and 22% of 
the patients were premenopausal in the good and poor 
prognosis group, respectively (P = 0.02, Fisher exact test). 
Estrogen receptor immunoexpression was positive in 12/19 
Table 1. Characteristics of breast carcinoma patients who had 
fresh tissue collected during surgery for epithelial cell selection.
ID Age pT pN CS HG ER PR ErbB2
 1 49 1 1 II 1 (+) (+) (+)
 2 48 2 0 II 2 (-) (-) (-)
 3 78 2 0 II 2 (+) (+) (+)
 4 58 1 2 III 2 (+) (+) (-)
 5 85 2 0 II 2 (+) (+) (-)
 6 53 2 0 II 2 (+) (+) (-)
 7 43 1 0 I 2 (+) (+) (-)
 8 73 2 2 III 2 (+) (+) (-)
 9 56 2 3 III 3 (+) (+) (+)
10 52 1 0 I 3 (+) (+) (+)
11 85 3 1 III 2 (-) (-) (-)
12 54 2 3 III 2 (-) (-) (-)
13 47 1 1 II 2 (-) (+) (-)
14 76 2 1 II 2 (+) (+) (-)
15 58 1 1 II 1 (+) (-) (+)
16 46 1 0 I 1 (+) (+) (+)
17 40 2 1 II 1 (+) (+) ND
18 53 1 2 III 1 (+) (+) (+)
19 51 2 1 II 3 (+) (+) (-)
20 47 1 0 I 2 (+) (-) (-)
21 50 1 1 II 3 (+) (-) (-)
22 49 3 3 III 3 (+) (+) (-)
23 55 2 0 II 2 (+) (+) (-)
24 43 3 3 III 3 (+) (+) (-)
25 62 1 0 I 2 (+) (+) (+)
26 58 1 0 I 2 (+) (-) (-)
27 53 1 0 I ND (+) (+) (-)
28 70 1 0 I 2 (+) (+) (-)
29 42 1 0 I 3 (+) (+) (-)
30 91 1 0 I 3 (+) (+) (-)
ID = patient identification; Age = in years; pT = pathological tumor 
size; pN = pathological lymph node involvement; CS = clinical 
stage TNM (AJCC Cancer Staging Manual, 6th edition, 2003); 
HG = histologic grade; ER = estrogen receptor; PR = proges-
terone receptor; (+) positive and (-) negative immunoexpres-
sion; ErbB2(+) only if +++. ND = not determined. Blood samples 
were also collected from patients 1-13 to detect circulating tumor 
cells.
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and 2/7 patients of the good and poor prognosis groups, 
respectively (P = 0.190, Fisher exact test).
Sample harvesting and processing
Fresh tumor samples and corresponding peritumoral 
tissue situated at least 1 cm from the visual border of the 
tumor were collected during surgery. Tumor and peritu-
moral samples were individually subjected to mechanical 
disaggregation using scalpel blades and to enzymatic 
disaggregation using 2 mg/mL type 1 collagenase and 2 
mg/mL hyaluronidase (Sigma-Aldrich, UK) for 18 h at 37°C, 
with intermittent shaking. After filtering, the resulting cell 
suspension was submitted to epithelial cell positive selec-
tion with Dynabead (CELLection Epithelial Enrich, Dynal 
Biotech, USA).
Tumor cells released from the primary site into vascular 
channels may be detected in the mononuclear compartment 
of blood samples. To avoid contamination with cutaneous 
epithelial cells, the first 3 mL blood was discarded after 
venipuncture and 10 mL blood was collected with a second 
syringe. Mononuclear cells (MNCs) were recovered after 
a density gradient using Ficoll-Paque PLUS (Amersham 
Biosciences, GE HealthCare Bio-Sciences Corp., USA).
Immunomagnetic epithelial cell separation
Dynabeads, used for epithelial cell selection, are super-
paramagnetic polystyrene beads coated with anti-human 
Ber-EP4 antibody, directed against a 34- and 49-kD glyco-
peptide expressed by human epithelial cells (10).
Each tumor (or peritumoral) cell suspension was mixed 
with 125 µL Dynabeads for 3 h at 4°C with gentle rotation. 
The rosetted cells were isolated by placing the tube in a 
Dynal magnetic particle concentrator (Dynal Biotech) for 6 
min at 4°C. The same procedure was carried out to recover 
epithelial cells from blood mononuclear cells, which were 
incubated with 25 µL Dynabeads.
To evaluate the efficacy of cell enrichment using this 
procedure, MCF-7 breast cancer cells were co-cultivated 
with fibroblasts (F) for 48 h (1 F:10 MCF-7) and, after trypsini-
zation, the cell suspension was incubated with Dynabeads 
as described. Cytospins revealed that all recovered cells 
were cytokeratin-positive (data not shown).
RNA extraction, reverse transcription and real-time 
RT-PCR
Total RNA was isolated using the Trizol reagent (Invitro-
gen Life Technologies, USA) according to the manufacturer 
protocol. One microgram RNA was incubated for 15 min at 
room temperature with DNase I (1 U/μg; Invitrogen). RNA 
quality was confirmed by absorbance measurement ratio 
260/280, which was >1.7, and by observation of 18S/28S 
rRNA by agarose gel (1%) electrophoresis under denaturing 
conditions and visualization with ethidium bromide (ratio 
>1.0). The reverse transcription reaction was carried out 
using hexamer random primers (Amersham Biosciences), 
dNTPs and Superscript™ (Invitrogen Life Technologies).
PCR primer sets (Table 3) were designed based on full 
length gene sequences in separated exons, in the coding 
region closer to the 3’ end of the gene using the software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). 
BLAST analysis of the primers was carried out to confirm 
uniqueness at www.ncbi.nlm.nih.gov/blast.
Amplification reactions were carried out using 2 µL 
cDNA diluted 1:10, platinum Taq polymerase (Invitrogen); 
Table 2. Characteristics of breast carcinoma patients with a long-
term follow-up (at least 5 years) who had paraffin-embedded tu-
mor samples available for analysis.
ID PG Age pT pN CS ER
 1 G 45 2 0 II (-)
 2 G 36 2 0 II (-)
 3 G 41 1 0 I (-)
 4 G 64 2 0 II (+)
 5 G 42 2 0 II (-)
 6 G 44 1 0 I ND
 7 G 43 1 0 I (-)
 8 G 70 1 0 I (+)
 9 G 56 1 0 I (+)
10 G 51 2 0 II (+)
11 G 41 2 0 II (+)
12 G 36 1 0 I (+)
13 G 56 1 0 I (+)
14 G 43 2 0 II (+)
15 G 46 2 0 II (+)
16 G 48 2 0 II (+)
17 G 55 1 0 I (+)
18 G 72 2 0 II (-)
19 G 46 x 0 ND (+)
20 G 39 1 0 I ND
21 G 41 2 0 II (-)
22 P 58 3 3 III (-)
23 P 77 3 2 IV ND
24 P 75 4 2 III ND
25 P 49 2 1 II (-)
26 P 63 2 3 III (+)
27 P 73 4 1 III (+)
28 P 61 1 2 III (-)
29 P 39 2 2 III (-)
30 P 61 4 3 III (-)
ID = patient identification; PG = prognostic group: G (good, no 
lymph node involvement at diagnosis and no regional or distant 
metastasis during follow-up), P (poor, positive node involve-
ment at diagnosis and distant metastasis at diagnosis (patient 
23) or during follow-up, followed by breast cancer death); Age = 
in years; pT = pathological tumor size; pN = pathological lymph 
node involvement; CS = clinical stage TNM (AJCC Cancer Stag-
ing Manual, 6th edition, 2003); ER = estrogen receptor; ND = not 
determined.
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and SYBR® Green I (Sigma-Aldrich), using a LightCycler™ 
(Roche Diagnostics, Germany) or a Rotor-gene system 
(Corbett Research, Australia). Conditions consisted of 95°C 
for 2 min, followed by 40 cycles at 94°C for 15 s, 60°C for 
30 s and 72°C for 30 s. Experiments were performed in 
duplicate. 
Expression of five housekeeping genes (ACTB, TFRC, 
GUSB, PPIA, and RPLP0) was first tested in 15 breast can-
cer samples (11) and expression of ACTB and RPLP0 was 
the most stable among samples. ACTB was then chosen as 
a reference gene. Relative expression of genes of interest 
was normalized to that of HB4A cells (normal mammary 
epithelial lineage). Investigated transcripts showed high 
real-time PCR efficiency rates (around 1.0) and relative 
expression was calculated as 2-ΔΔCT. Results were then 
transformed to their natural logarithm values.
Detection of circulating epithelial cells using nested 
RT-PCR
Epithelial cells recovered from peripheral blood MNCs 
after immunoselection with Dynabeads had their mRNA 
extracted and processed by nested PCR to evaluate the 
expression of cytokeratin 19 (KRT19), a protein expressed 
by epithelial cells. The first reaction took place in the pres-
ence of 1 µL cDNA, Taq recombinant DNA Polymerase 
(Invitrogen) and external primers (Table 3). Amplification 
conditions consisted of 95°C for 2 min, followed by 35 cycles 
at 95°C for 15 s, 62°C for 1 min, and 72°C for 1 min. The 
second PCR was performed using 1 µL of the product of the 
first reaction and a second pair of internal primers (Table 
3), under the same conditions as described above, for 25 
amplification cycles. The product was detected under UV 
light as a band of 461 bp on 2% agarose gel containing 
ethidium bromide.
To establish the ideal number of amplification cycles, 
a serial dilution of HB4A cells (2, 5 and 10 cells) with pro-
myelocytic leukemia HL60 cells (1 x 106) was performed. 
The first round of PCR revealed no product. The second 
PCR, performed using a variable number of cycles, revealed 
a characteristic product after 25 cycles for all dilutions of 
HB4A cells in HL60 cells (Figure 1A).
Immunohistochemistry
Sections (3-µm thick) were cut from paraffin blocks 
containing invasive cancer, and immunohistochemistry 
reactions were carried out to detect E-cadherin (mouse 
monoclonal IgG1 anti-human antibody, clone NCH-38, 
DAKO M3612, dilution 1:100) (DAKO Corporation, USA) 
or SNAI1 [(E-18): sc-10432 goat polyclonal IgG anti-human 
SNAI1 internal region; Santa Cruz Biotechnology, Inc., 
USA, dilution 1:50] with antigen retrieval performed by 
pressure cooking in 10-mM citrate buffer at pH 6.0 for 4 
min. Detection was done using the StreptAB Complex/
HRP duet (Dako k492, 1:200) or horseradish peroxidase 
anti-goat IgG conjugate (Vector Labs, USA) and DAB 
(Sigma D5637; Sigma-Aldrich Corp., USA).
E-cadherin staining was evaluated as negative, if 
absent or low (no immunostaining or immunopositivity 
≤10% or low-intensity partial membrane staining in >10% 
of cells) or positive (low, moderate or intense complete 
membrane staining in >10% of cells). The entire tumor 
represented in the section was assessed. Appropriate 
positive and negative controls were run with each batch 
(lobular and ductal invasive carcinomas).
Snail expression was evaluated as negative (nil 
or ≤10% of cells) or positive (>10% of cells). Negative 
controls were obtained by the omission of the primary 
antibody. Immunostaining for Snail was mainly observed 
in the cytoplasm and only two patients presented nuclear 
staining.
Statistical analysis
The Kolmogorov-Smirnov test of normality was applied 
to verify the distribution pattern of expression values. A 
normal distribution was detected for expression values of 
matched tumor/peritumor samples and therefore paramet-
ric tests (paired t-test and Pearson correlation) were used. 
When normal distribution was not detected, non-parametric 
tests (Mann-Whitney for independent variables, and Spear-
man correlation) were used. The level of significance was 
set at ≤0.05 in all analyses. Association between variables 
was determined using the Fisher exact test. The SPSS 
statistical software version 11.0 (USA) was used.
Table 3. Primer sequences used in RT-PCR.
Gene Genbank accession number Primer sense (5’-3’) Primer antisense (5’-3’) Product size (bp)
CK19 NM_002276 CACTACTACACGACCATCCAGGAC CAAATTGTTGTAGTGATCTTCCTG 798
CK19 NM_002276 TTTGAGACGGAACAGGCTCT TCTTCCAAGGCAGCTTTCAT 461
CDH1 NM_004360 CTTGGTCTACGCCTGGGACT TGTGAGCAATTCTGCTTGGA 150
SNAI1 NM_00598 TGGGTGAATTCGGGCTTG CAAGATGCACATCCGAAGC 134
HAKAI NM_024814 TCACTGCACAGGATCACTAC TAAAGGGGGTGAGCTGTTTG 243
ACTB NM_001101 AGAAAATCTGGCACCAACC AGAGGCGTACAGGGATAGCA 188
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Results
A paired analysis of the expression of E-cadherin 
(CDH1), Snail (SNAI1) and Hakai transcripts between the 
selected epithelial malignant component of tumors and its 
adjacent normal tissue was performed. Our data indicate 
that the expression levels of these target genes are widely 
distributed (Figure 2), irrespective of the tissue origin (tumor 
or normal).
CDH1 mRNA expression was evaluated in 22 paired 
samples and a positive correlation was detected between 
them (r = 0.697; P < 0.01; Pearson correlation); however, 
no differential expression between the primary tumor (0.12 
± 2.51) and corresponding peritumoral tissue (-0.34 ± 2.45) 
was observed (Figure 2). SNAI1 mRNA expression was 
evaluated in 25 paired samples and neither differential 
expression (primary tumor = 3.59 ± 2.31 vs peritumoral 
tissue = 3.59 ± 2.31) nor correlation between pairs was 
detected. Hakai mRNA expression was determined in 22 
paired samples and no correlation was observed. Although 
there was no significant differential expression of HAKAI 
between matched samples (primary tumor = 2.30 ± 2.47 
vs peritumoral tissue = 1.28 ± 2.67), 12 tumor specimens 
showed a higher expression (samples 4, 5, 11, 12, 15, 16, 
18, 21, 22, 24, 28, 29) compared to the corresponding 
peritumoral samples (Figure 2).
A positive correlation was detected between tumoral 
expression of E-cadherin and Snail (N = 18, r = 0.564, P 
= 0.015, Spearman correlation) and Snail and Hakai (N = 
19, r = 0.611, P = 0.005, Spearman correlation). A trend 
towards a positive correlation between E-cadherin and 
Hakai expression was also observed (N = 15, r = 0.454, P 
= 0.089, Spearman correlation).
mRNA expression of all three target genes was ana-
lyzed in 13 matched samples (tumor and peritumoral) and 
discriminant analysis was performed using these variables. 
However, only 65.4% of the originally grouped cases would 
be correctly classified (Figure 3), indicating that these pa-
rameters could not be used for this purpose.
We then evaluated whether there were differences in 
tumor gene expression between patients with involved 
nodes and patients with uninvolved nodes. However, we 
observed no differences in E-cadherin, Snail or Hakai mRNA 
tumor expression according to the presence of regional 
metastases (Figure 4A).
We also determined whether E-cadherin, Snail and 
Figure 1. KRT19 detection by nested RT-PCR. A, HB4A cells [T1 (N = 2 cells); T2 (N = 5 cells); T3 (N = 10 cells] were diluted in 106 HL60 cells. 
Experiments were performed in duplicate (a and b). Epithelial cells were recovered with Dynabeads and, after nested PCR, bands of 461 and 
178 bp corresponding to KRT19 and ACTB were visible. HB4A and HL60 cells were used as positive and negative controls, respectively. B, 
Circulating tumor cells (CT) as detected by KRT19 expression by nested RT-PCR in mononuclear cells obtained from the peripheral blood of 
breast cancer patients. Bands of 461 and 178 bp corresponding to KRT19 and ACTB may be seen in samples from three patients. MCF7 and/
or HB4A cells were used as positive control and a pool of lymphocytes obtained from three healthy individuals (FN), as negative controls.
E-cadherin, Snail and Hakai expression in ductal carcinomas 1133
www.bjournal.com.br Braz J Med Biol Res 42(12) 2009
Figure 2. CDH1, SNAI1, and HAKAI mRNA expression in epithelial 
cells isolated from the primary tumor site and its normal adjacent tis-
sue. Epithelial cells from tumor (T) and peritumoral (P) sites were 
recovered separately by immunomagnetic positive selection. Relative 
expression was calculated as described in Methods and is shown on 
the y-axis as its natural logarithm (Ln) value. Individual expression 
values are shown and sample identification appears on the x-axis. 
Not all 30 specimens had the expression values for the three target 
genes evaluated in paired samples. Since data followed a normal dis-
tribution, the paired t-test was employed and P values appear inside 
the figures.
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Figure 3. Three-dimensional distribution of tumor (T) and peritu-
moral (P) samples according to CDH1, SNAI1 and HAKAI mRNA 
expression. Thirteen patients had all three target genes evaluated 
in matched samples. Discriminant analysis classified 65.4% of the 
samples in the correct group.
Figure 4. A, CDH1, SNAI1, and HAKAI mRNA expression in tumor specimens according to the presence [N(+)] or absence of lymph 
node involvement [N(-)]. Boxplots display the distribution of all values between bars (25th, 50th and 75th percentiles in the box), except 
outliers (circles, 1.5-3.0 box lengths from the 75th quartile; asterisks, >3.0 box lengths from the 75th percentile). No differences were 
observed (Mann-Whitney test). B, CDH1, SNAI1, and HAKAI mRNA expression in tumor specimens according to the presence of 
circulating tumor cells (CTC) [presence (+) or absence (-)].
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Hakai mRNA tumor expression was associated with the 
presence of circulating malignant cells, as determined by 
KRT19 expression in blood MNCs (Figure 1B). Circulating 
tumor cells were detected in blood samples from three of 
13 patients. Boxplots (Figure 4B) suggest that there was 
a trend towards a lower E-cadherin mRNA expression (but 
not Snail or Hakai) in tumor samples from these patients 
with circulating tumor cells.
In addition, we determined whether E-cadherin and 
Snail immunoexpression could be associated with breast 
cancer distant metastases and death in another group of 
patients with a minimum follow-up of five years (Figure 
5). Negative E-cadherin expression was observed in 6 
samples, 4 of them belonging to the poor prognosis group 
(Table 4) and inversely, positive E-cadherin expression 
was observed in 24 tumor specimens, 19 of them from the 
good prognosis group. These data indicate an association 
between E-cadherin protein negativity and poor prognosis 
and, conversely, between positivity and good prognosis 
(Table 4). Positive Snail expression was observed in 16 
samples but no association with the prognosis group was 
detected (Table 4).
Discussion
Our assumption was that invasive ductal carcinomas 
might present changes in E-cadherin, Snail or Hakai mRNA 
expression as compared to their paired normal adjacent 
tissue; however, no differential expression was observed. 
Our data indicate that invasive carcinomas and their normal 
adjacent tissue share the same characteristics concerning 
the mRNA expression of these genes, i.e., if expression is 
low in the tumor, it is also low in the normal adjacent tissue 
and vice-versa. One limitation of our study was the small 
sample size, its strength was that the epithelial compo-
Figure 5. E-cadherin and Snail immunoexpression in breast cancer specimens. A and C, E-cadherin membranous-positive expression 
in tumor cells and Snail-negative expression in a specimen from a patient from the good prognosis group (Pt 5). B, Negative immuno-
staining for E-cadherin in a tumor sample from a patient assigned to the poor prognosis group (Pt 24). D, Snail-positive tumor immu-
noexpression in a patient (Pt 9) from the good prognosis group. Snail immunoexpression was mainly observed in the cytoplasm (40X).
Table 4. E-cadherin and Snail immunoexpression in breast 
cancer specimens from patients assigned to the good and poor 
prognosis groups. 
Good prognosis Poor prognosis
E-cadherin(-) 2 4
E-cadherin(+) 19* 5
Snail(-) 8 6
Snail(+) 13 3
*P < 0.05 E-cadherin expression in good vs poor prognosis 
groups (Fisher exact test).
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nent was individually analyzed using a sensitive method, 
which may allow measurements of expression levels as 
a continuous variable. In addition, three target genes, E-
cadherin, Snail and Hakai, were concomitantly analyzed in 
the matched samples. Another study, carried out on a larger 
sample of matched tumor and metastasis specimens from 
ductal carcinomas, did not detect differences in E-cadherin 
protein staining intensity (9). Taken together, these results 
and ours suggest that, in general, ductal carcinomas, rep-
resented by the primary tumor, its peritumoral tissue and 
its nodal metastases, maintain their E-cadherin expression 
throughout their development, including invasiveness and 
establishment in other tissues. On the other hand, a re-
duction of E-cadherin protein expression was reported in 
a small series of invasive ductal carcinomas as compared 
to ductal carcinomas in situ (12). Differences between this 
analysis and ours were that samples were obtained from 
different patients and were not paired in the previous study. 
It was also reported that reduction or lack of E-cadherin 
protein expression in non-lobular breast cancer is prefer-
entially found in basal-like carcinomas (13). However, our 
samples were mainly represented by hormone receptor-
positive tumors. Another consideration is that both studies 
analyzed E-cadherin protein expression, which is also 
regulated post-transcriptionally. In our study, Hakai mRNA 
was more expressed in 12/22 tumors compared to their 
matched peritumor samples, suggesting that E-cadherin 
degradation mediated by Hakai may be up-regulated at 
least in a few tumors. In addition, other mechanisms may 
be involved in E-cadherin down-regulation at the protein 
level (14,15) that may occur through endocytosis (16,17), 
and these were not investigated here.
A positive correlation between Snail and E-cadherin 
mRNA expression in invasive ductal carcinoma samples 
has been reported (18), as also observed in the present 
study. In addition, although in vitro studies using cell lines 
have indicated that induced overexpression of Snail in 
mammary normal or transformed cell lines represses E-
cadherin transcription, the same does not seem to occur in 
tumor samples (18). Hence, observations in breast tumor 
samples underscore the role of other regulatory elements 
in addition to Snail in physiologic E-cadherin transcription 
regulation.
We also evaluated whether tumor expression of 
E-cadherin, Snail and Hakai mRNA could be related to 
regional metastasis since the presence of involved lymph 
nodes suggests that tumor spreading may have occurred 
through the lymphatics. However, we could not find any 
association. In agreement, no relation between lymph node 
involvement and E-cadherin immunohistochemical expres-
sion was detected by others in non-lobular carcinomas 
(8,19). Conversely, Snail overexpression in tumors from 
patients with node (18,20) and distant metastases (21) has 
also been reported.
Circulating tumor cells were detected in three of the 
13 patients tested, in agreement with results previously 
reported in clinical stage I-III breast cancer disease (22,23). 
Although we studied a small number of samples, we may 
speculate that there may be a trend towards a low E-cadherin 
expression in tumor samples from patients with circulating 
malignant cells that could facilitate tumor shedding through 
the vascular channels. Other investigators have not found 
a relation between blood vessel invasion and E-cadherin 
expression (24). However, their sample also included 
lobular and other carcinoma samples and not just ductal 
carcinomas.
Complete absence of E-cadherin protein immunoex-
pression was observed in 10% of the tumors analyzed here, 
in agreement with data reported by others (8,13,25,26). In 
addition, positive E-cadherin expression was associated 
with a better prognosis, in agreement with a previous 
report (19).
We detected Snail protein nuclear localization in just 
two of the 30 samples analyzed. Similarly, Rosivatz et al. 
(26), studying a large series of adenocarcinomas of the 
upper gastrointestinal tract, observed nuclear Snail immu-
noreactivity in only 7.9% of them. We speculate that Snail 
may not be exerting its function as a transcriptional factor 
in ductal carcinomas.
This is the first report to analyze the concomitant expres-
sion of CDH1, SNAI1 and Hakai mRNA in matched tumor 
and peritumoral samples from patients with invasive ductal 
carcinomas. Our data suggest that there is no clear pattern 
of expression of these target genes that may classify the 
tumor specimen and its adjacent normal tissue. Our study 
also indicates that tumor E-cadherin protein expression 
may be related to overall breast cancer survival.
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